Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Clinical & Experimental Metastasis|June 22, 2024
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2Levent Mutlu, Blair McNamara, Stefania Bellone, et al.
Gynecologic Oncology|January 7, 2023
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expressionDennis Mauricio, Stefania Bellone, Levent Mutlu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2024
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)Sangini S Sheth, Ji Eun Oh, Stefania Bellone, et al.
Gynecologic Oncology|November 28, 2022
Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcomaJustin Harold, Stefania Bellone, Diego D Manavella, et al.
Gynecologic Oncology|May 22, 2022
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitorJoan R Tymon-Rosario, Paola Manara, Diego D Manavella, et al.
Gynecologic Oncology|December 16, 2022
Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitorDiego D Manavella, Blair McNamara, Justin Harold, et al.
Molecular Cancer Therapeutics|September 7, 2023
In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous CarcinomaLevent Mutlu, Diego D Manavella, Stefania Bellone, et al.
Gynecologic Oncology|March 23, 2023
Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitorBlair McNamara, Justin Harold, Diego Manavella, et al.
Turk Patoloji Dergisi|September 12, 2013
HPV types in Turkey: multicenter hospital based evaluation of 6388 patients in Turkish gynecologic oncology group centersPolat Dursun, Ali Ayhan, Levent Mutlu, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 16, 2024
Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervixStefania Bellone, Kyungjo Jeong, Mari Kyllesø Halle, et al.
Pageof 4